Morten Hostrup, PhD
15
4
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle
Role: lead
U-LABA/ICS Effects on Exercise Performance, Vilanterol
Role: lead
Testosterone-induced Muscle Memory and Underlying Mechanisms
Role: lead
Role of Lung Function for Exercise Capacity in Well-trained Individuals
Role: lead
U-LABA/ICS Effects on Exercise Performance, Indacaterol
Role: lead
U-LABA/ICS Effects on Exercise Performance, Formoterol
Role: lead
Proteome Remodelling
Role: lead
Effects of BFR Interventions in Healthy Individuals and Individuals With COPD
Role: lead
Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans
Role: lead
Effects of Combinations of Performance-enhancing Supplements on Exercise Performance
Role: lead
Effect of Exercise on Muscle Proteome Signature
Role: lead
Regulation of Metabolism and Ion Handling
Role: lead
Beta2-adrenergic Agonism and Muscle Remodelling
Role: lead
Exosome Proteomics to Detect EPO
Role: lead
Effect of Training Intensity on Health Outcomes in Diabetes
Role: lead
All 15 trials loaded